Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGB1 | P09429 | 2/20 | 0.60 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | LDHB | P07195 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369577 | 0.86 | HMGB1 (0.73) | HMGB1CXCL12TSHRPTPN1PTPN2 | |
| SCHEMBL5212920 | 0.86 | HMGB1 (0.46) | HMGB1CXCL12TSHRPTPN1PTPN2 | |
| SCHEMBL5524279 | 0.83 | HMGB1 (0.58) | HMGB1CXCL12TSHRPTPN1PTPN2 | |
| SCHEMBL28205348 | 0.81 | TSHR (0.61) | TSHRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29688181 | 0.79 | HMGB1 (0.83) | HMGB1CXCL12PTPN1PTPN2PTPN6 | |
| SCHEMBL1129138 | 0.79 | HMGB1 (0.83) | HMGB1CXCL12PTPN1PTPN2PTPN6 | |
| SCHEMBL23003 | 0.79 | TSHR (0.79) | TSHRPTPN1PTPN2PTPN6ALDH1A1 | |
| SCHEMBL1395559 | 0.78 | PTPN1 (0.72) | HMGB1CXCL12PTPN1PTPN2PTPN6 | |
| SCHEMBL29688190 | 0.78 | PTPN1 (0.72) | HMGB1CXCL12PTPN1PTPN2PTPN6 | |
| SCHEMBL4908158 | 0.78 | TSHR (0.72) | TSHRPTPN1PTPN2PTPN6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403254-B1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-09-17 | — | — | EP | disclosed |
| US-7875467-B2 | Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7611909-B1 | Acridinium compound for use in the concurrent detection of target analytes in immunoassays or nucleic acid assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1104405-B1 | NEAR INFRARED CHEMILUMINESCENT ACRIDINIUM COMPOUNDS AND USES THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090029349-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080305557-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2008-12-11 | — | — | US | disclosed |
| US-7319041-B2 | Applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2008-01-15 | — | — | US | disclosed |
| US-7083986-B2 | Near infrared chemiluminescent acridinium compounds and uses thereof | BAYER HEALTHCARE LLC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | BAYER CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1403254-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | Bayer Healthcare, LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20020076823-A1 | Near infrared chemiluminescent acridinium compounds and uses thereof | BAYER CORPORATION (US) | 2002-06-20 | — | — | US | disclosed |
| US-6355803-B1 | COMPOUND COMPRISING EXTENDED, COPLANAR, CONJUGATED SYSTEM, FORMED BY ATTACHMENT OF FUNCTIONAL GROUP COMPRISING AROMATIC RING AND ELECTRON-DONATING GROUP ON ACRIDINIUM NUCLEUS, WHICH MAINTAINS COPLANARITY DURING LIGHT EMISSION | BAYER CORPORATION | 2002-03-12 | — | — | US | disclosed |
| EP-1104405-A1 | NEAR INFRARED CHEMILUMINESCENT ACRIDINIUM COMPOUNDS AND USES THEREOF | Bayer Corporation (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009487-A9 | NEAR INFRARED CHEMILUMINESCENT ACRIDINIUM COMPOUNDS AND USES THEREOF | BAYER AG (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000009487-A1 | NEAR INFRARED CHEMILUMINESCENT ACRIDINIUM COMPOUNDS AND USES THEREOF | BAYER CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | ACR, SSB, NASP | HMGB1 1566/4885CXCL12 4429/4885TSHR 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.